Compare THS & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THS | MLTX |
|---|---|---|
| Founded | 2021 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 972.7M |
| IPO Year | N/A | N/A |
| Metric | THS | MLTX |
|---|---|---|
| Price | $23.72 | $14.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $24.67 | ★ $36.33 |
| AVG Volume (30 Days) | 1.6M | ★ 2.0M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,336,000,000.00 | N/A |
| Revenue This Year | $1.43 | N/A |
| Revenue Next Year | $0.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.85 | $5.95 |
| 52 Week High | $40.77 | $62.75 |
| Indicator | THS | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.19 | 57.57 |
| Support Level | $23.70 | $12.48 |
| Resistance Level | $24.09 | $14.11 |
| Average True Range (ATR) | 0.28 | 0.77 |
| MACD | -0.12 | 0.53 |
| Stochastic Oscillator | 50.00 | 86.30 |
TreeHouse Foods is the largest pure-play private-label manufacturer in the US. Much larger in the past following the 2016 acquisition of Ralcorp, Conagra's former private-label business, the company has since divested several businesses to focus on high-growth categories. At present, the company produces and sells snacks (crackers, pretzels, cookies, and so on), beverages (such as nondairy creamer, coffee, tea, broth), and a select number of grocery products (pickles, refrigerated dough, hot cereal, cheese, and pudding). Its most important sales channel is through retail grocery stores that sell its products under their own brands, with co-manufacturing and food away from home as much smaller channels of distribution for its fare.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.